Aldeyra Therapeutics Appoints Chip Clark to Board of Directors Lexington, Mass.

Aldeyra Therapeutics Appoints Chip Clark to Board

Lexington, Mass., April

17, 2025 - Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing

innovative therapies designed to treat immune-mediated and metabolic diseases, today announced the appointment of Chip Clark to the

company's board of directors.

"Chip possesses a wealth of experience leading innovative biotechnology

companies," stated Richard H. Douglas, Ph.D., Chairman of the Board at Aldeyra Therapeutics. "We look forward to leveraging

his expertise as Aldeyra continues to advance a pipeline focused on addressing significant unmet medical needs in immune-mediated and

metabolic diseases."

Mr. Clark has more than three decades of leadership experience in

the biopharmaceutical industry. He currently serves as Co-founder and Chief Executive Officer of Vibrant Biomedicines, a venture-backed

company developing vaccines that target bacterial pathogens. Before co-founding Vibrant Biomedicines, Mr. Clark served as Chief Executive

Officer of Genocea Biosciences, Inc. Prior to Genocea, he held the role of Chief Business Officer at Vanda Pharmaceuticals Inc., a publicly

traded biotechnology company he co-founded in 2004. Prior to his tenure at Vanda, Mr. Clark was a Principal at Care Capital, LLC, a venture

capital firm focused on investments in biopharmaceutical companies. Mr. Clark began his career at SmithKline Beecham Corporation, now

part of GlaxoSmithKline plc, where he spent 10 years in a range of management positions. Mr. Clark holds a Master of Business Administration

from The Wharton School of the University of Pennsylvania and a Bachelor of Arts from Harvard University.

"Across a variety of mass-market and orphan diseases, Aldeyra's

diversified pipeline represents novel approaches for the treatment of unmet medical need," Mr. Clark stated. "I am excited

to join Aldeyra's Board of Directors as the company continues to progress towards providing patients and healthcare providers new

therapeutic options."

Aldeyra Therapeutics is a biotechnology company devoted to discovering

innovative therapies designed to treat immune-mediated and metabolic diseases. Our approach is to develop pharmaceuticals that modulate

protein systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at

once while minimizing toxicity. Our product candidates include RASP (reactive aldehyde species) modulators ADX-629, ADX-248, ADX-743,

ADX-631, ADX-246, and chemically related molecules for the potential treatment of systemic and retinal immune-mediated and metabolic diseases.

Our late-stage product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis,

and ADX-2191, a novel formulation of intravitreal methotrexate for the potential treatment of retinitis pigmentosa.

Safe Harbor Statement

This release contains forward-looking statements within the meaning of

the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding Aldeyra's future expectations,

plans, and prospects, including without limitation statements regarding: the goals, opportunity, and potential for reproxalap and our

other product candidates. Aldeyra intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking

statements contained in Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. In

some cases, you can identify forward-looking statements by terms such as, but not limited to, "may," "might,"

"will," "objective," "intend," "should," "could," "can," "would,"

"expect," "believe," "anticipate," "project," "on track," "scheduled,"

"target," "design," "estimate," "predict," "contemplates," "likely,"

"potential," "continue," "ongoing," "aim," "plan," or the negative of these

terms, and similar expressions intended to identify forward-looking statements. Such forward-looking statements are based upon current

expectations that involve risks, changes in circumstances, assumptions, and uncertainties. Aldeyra is at an early stage of development

and may not ever have any products that generate significant revenue. All of Aldeyra's development timelines may be subject to adjustment

depending on recruitment rate, regulatory review, preclinical and clinical results, funding, and other factors that could delay the initiation,

enrollment, or completion of clinical trials. Important factors that could cause actual results to differ materially from those reflected

in Aldeyra's forward-looking statements include, among others, the timing of enrollment, commencement and completion of Aldeyra's clinical

trials, the timing and success of preclinical studies and clinical trials conducted by Aldeyra and its development partners; delay in

or failure to obtain regulatory approval of Aldeyra's product candidates, including as a result of the FDA not accepting Aldeyra's

regulatory filings, issuing a complete response letter, or requiring additional clinical trials or data prior to review or approval of

such filings or in connection with resubmissions of such filings; the ability to maintain regulatory approval of Aldeyra's product candidates,

and the labeling for any approved products; the risk that prior results, such as signals of safety, activity, or durability of effect,

observed from preclinical or clinical trials, will not be replicated or will not continue in ongoing or future studies or clinical trials

involving Aldeyra's product candidates in clinical trials focused on the same or different indications; the scope, progress, expansion,

and costs of developing and commercializing Aldeyra's product candidates; uncertainty as to Aldeyra's ability to commercialize (alone

or with others) and obtain reimbursement for Aldeyra's product candidates following regulatory approval, if any; the size and growth of

the potential markets and pricing for Aldeyra's product candidates and the ability to serve those markets; Aldeyra's expectations regarding

Aldeyra's expenses and future revenue, the timing of future revenue, the sufficiency or use of Aldeyra's cash resources and needs for

additional financing; the rate and degree of market acceptance of any of Aldeyra's product candidates; Aldeyra's expectations regarding

competition; Aldeyra's anticipated growth strategies; Aldeyra's ability to attract or retain key personnel; Aldeyra's commercialization,

marketing and manufacturing capabilities and strategy; Aldeyra's ability to establish and maintain development partnerships; Aldeyra's

ability to successfully integrate acquisitions into its business; Aldeyra's expectations regarding federal, state, and foreign regulatory

requirements; political, economic, legal, social, and health risks, public health measures, and war or other military actions, that may

affect Aldeyra's business or the global economy; regulatory developments in the United States and foreign countries; Aldeyra's ability

to obtain and maintain intellectual property protection for its product candidates; the anticipated trends and challenges in Aldeyra's

business and the market in which it operates; and other factors that are described in the "Risk Factors" and "Management's

Discussion and Analysis of Financial Condition and Results of Operations" sections of Aldeyra's Annual Report on Form 10-K for the

year ended December 31, 2024, which is on file with the Securities and Exchange Commission (SEC) and available on the SEC's website at

https://www.sec.gov/. Additional factors may be described in those sections of Aldeyra's Quarterly Report on Form 10-Q for the quarter

ended March 31, 2025, expected to be filed with the SEC in the second quarter of 2025, and Aldeyra's other filings with the SEC.

In addition to the risks described above and in Aldeyra's other filings

with the SEC, other unknown or unpredictable factors also could affect Aldeyra's results. No forward-looking statements can be guaranteed

and actual results may differ materially from such statements. The information in this release is provided only as of the date of this

release, and Aldeyra undertakes no obligation to update any forward-looking statements contained in this release on account of new information,

future events, or otherwise, except as required by law.